Key Points
- CFO Asif Ali sold 58,629 PTGX shares at an average price of $141.78, generating approximately $8.31 million. The Rule 10b5-1 transaction reduced his direct ownership by 49.84% to 59,003 shares.
- Protagonist Therapeutics reported quarterly EPS of $2.29, slightly above estimates, on $213.47 million in revenue—up 3,746.8% year over year. Analysts expect $4.22 in full-year EPS.
- Wall Street maintains a Moderate Buy consensus, with 16 Buy ratings and two Holds and an average price target of $147.13. Institutional investors own 98.63% of the company.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CFO Asif Ali sold 58,629 shares of the stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total value of $8,312,419.62. Following the transaction, the chief financial officer directly owned 59,003 shares in the company, valued at $8,365,445.34. The trade was a 49.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Protagonist Therapeutics Price Performance
PTGX stock opened at $140.06 on Friday. Protagonist Therapeutics, Inc. has a 1 year low of $62.24 and a 1 year high of $160.81. The company has a market cap of $9.06 billion, a P/E ratio of 135.98 and a beta of 1.53. The stock's fifty day moving average price is $145.17 and its 200-day moving average price is $122.19.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, beating analysts' consensus estimates of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The company had revenue of $213.47 million during the quarter, compared to analysts' expectations of $212.03 million. The business's revenue for the quarter was up 3746.8% on a year-over-year basis. As a group, analysts expect that Protagonist Therapeutics, Inc. will post 4.22 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have commented on PTGX. Wall Street Zen upgraded shares of Protagonist Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 22nd. Johnson Rice set a $165.00 target price on Protagonist Therapeutics in a research report on Friday, July 17th. Weiss Ratings upgraded shares of Protagonist Therapeutics from a "sell (d+)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Wolfe Research reaffirmed an "outperform" rating on shares of Protagonist Therapeutics in a research note on Monday, August 31st. Finally, Citigroup raised their target price on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the stock a "buy" rating in a report on Monday, August 31st. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $147.13.
View Our Latest Stock Analysis on PTGX
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sumitomo Mitsui Trust Group Inc. lifted its position in Protagonist Therapeutics by 7.8% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,760 shares of the company's stock valued at $291,000 after acquiring an additional 200 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Protagonist Therapeutics by 7.2% in the 2nd quarter. GAMMA Investing LLC now owns 3,109 shares of the company's stock valued at $381,000 after acquiring an additional 208 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Protagonist Therapeutics by 8.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company's stock valued at $258,000 after purchasing an additional 221 shares during the period. Keating Financial Advisory Services Inc. acquired a new position in Protagonist Therapeutics in the 2nd quarter worth approximately $30,000. Finally, Allworth Financial LP acquired a new stake in shares of Protagonist Therapeutics in the second quarter worth $31,000. 98.63% of the stock is currently owned by institutional investors.
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for chronic immune-mediated and hematologic diseases. The company uses its proprietary technology platform to design peptides intended to selectively interact with disease-relevant biological targets.
Protagonist's pipeline includes icotrokinra, formerly known as JNJ-2113, an investigational oral peptide that selectively targets the interleukin-23 receptor.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
